16:32 EST Arcutis Biotherapeutics (ARQT) files automatic mixed securities shelf
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARQT:
- Arcutis Biotherapeutics reports Q4 EPS 13c, consensus 9c
- Arcutis announces Max Homa joins ‘Free to Be Me’ campaign
- ARQT Earnings this Week: How Will it Perform?
- Arcutis Buy Rating: Zoryve’s Strengthened Pediatric Data and Undervalued Long-Term Revenue Potential
- Arcutis Biotherapeutics announces results for Phase 2 trial of Zoryve